Start here if you're new
what it is
Biomea is a lean clinical-stage biotech (on the order of a few dozen employees after recent rightsizing) trying to turn lab-made pills into treatments for cancer, diabetes, and obesity.
how it gets paid
Last year Biomea Fusion made n/a in revenue.
what just happened
Latest quarter operating revenue was effectively $0; Biomea still posted a meaningful net loss per share.
At a glance
C+ balance sheet — some cracks in the foundation
-$3.83 fy2024 eps est
1.0 beta
~$96M market cap
small cap
xvary composite: 41/100 — below average
What they do
Biomea is a lean clinical-stage biotech trying to turn lab-made pills into treatments for cancer, diabetes, and obesity.
The moat is narrow. Biomea says its FUSION platform helps design covalent small molecules, which means drugs that permanently bind to a target protein, so what: if the chemistry works, you may get stronger effects at lower doses. But with a $96 million market cap and an estimated 2024 loss of $3.83 a share, the science is still carrying the whole case.
How they make money
n/a
annual revenue
The products that matter
oral diabetes drug candidate
icovamenib
two phase ii trials
it is the lead asset and the center of gravity for the equity story. Phase II updates and longer follow-up are what investors trade against—check the company's disclosures for the latest timing and data cuts.
lead program
oral obesity drug candidate
BMF-650
phase i/ii
this is the second shot on goal. milestones are set for 2026, which matters because a one-asset biotech with $0 revenue gets very little benefit of the doubt.
second asset
capital markets funding
balance sheet runway
C+ strength
for now, the balance sheet is effectively a product line. with no product revenue yet, financing determines how long the science gets to keep talking.
funding matters
Key numbers
-$3.83
2024 EPS est
EPS means profit per share—here the data stack uses a consensus-style ~-$3.83 FY2024 figure (same idea as the score strip), not an audited final you should treat as gospel without the 10-K.
$6M
long-term debt
Long-term debt means money owed over years, plain English: leverage is modest at $6M, so what: debt is not the fire here, operating losses are.
6%
debt to capital
Debt to capital means how much of the company is funded by borrowing, plain English: only 6% is debt-funded, so what: balance sheet stress comes more from burn than lenders.
5/100
price stability
Price stability means how steady the stock has been, plain English: Biomea has been extremely jumpy, so what: your position can swing hard on one headline.
Financial health
C+
strength
- balance sheet grade C+ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $6M (6% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for BMEA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest quarter revenue was $0, and Biomea still posted a $(0.27) loss per share (rounded).
Filings for the most recent quarter show essentially no operating revenue and a net loss near $16M, with per-share loss around $0.27 versus consensus near $0.29 — a small miss on EPS in a pre-revenue story.
$0
revenue
$(0.27)
eps
n/a
n/a
the number that mattered
The key number is roughly $(0.27) in quarterly EPS on $0 revenue, because it tells you Biomea is still far from self-funding.
source: company filings / EDGAR
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is clinical failure or weak durability data for icovamenib. with $0 revenue and a $96M market cap, most of the equity value is still a vote on the pipeline.
med
icovamenib does not hold up
The lead asset is in two Phase II trials for type 2 diabetes. If the March 2026 data set fails to support the thesis, there is no operating business underneath it to soften the landing.
Impact: the stock would be repriced against a $0 revenue base, which means most of the $96M market value is in play.
med
cash burn forces dilution
Estimated FY2024 EPS is around -$3.83 and revenue is still $0. That is biotech shorthand for one thing: the science is being financed by shareholders.
Impact: if trial work expands faster than cash resources, new equity can arrive before revenue ever does.
med
BMF-650 fails to broaden the story
The obesity program is only in Phase I/II. If 2026 milestones disappoint, BMEA falls back to being a single-lead-asset company in one of the market's most crowded therapeutic areas.
Impact: the addressable opportunity looks smaller, and analysts' $7.14 average target starts to look even more like wishful scenario math.
med
legal overhang keeps sentiment weak
Rosen Law Firm is investigating potential securities claims tied to 2024 events. That does not change the molecule, but it can keep the stock in penalty-box territory while investors wait for cleaner signals.
Impact: even good updates can get discounted when the tape already assumes more shoes may drop.
A forced rethink on either efficacy or financing would hit 100% of this story, because there is no commercial revenue stream to offset the damage.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical
icovamenib 52-week read-through
The March 14, 2026 presentation matters more than any headline target. You want to know whether investors treat the data as durable enough to justify staying in the story.
cash burn
losses versus runway
With revenue at $0 and quarterly losses still printing, each earnings update is really a financing update in disguise.
pipeline breadth
BMF-650 2026 milestones
If the obesity program gains credibility, the company stops looking like a one-asset bet. If it does not, the concentration risk gets louder.
sentiment
legal and trust overhang
The securities investigation may not change the science, but it can shape how quickly the market is willing to forgive weak communication or mixed data.
Analyst rankings
consensus target
$7.14
Analysts sit far above the current $1.34 price. in human-speak, they still think successful data could re-rate the stock hard.
beta
1.0
Beta says market-like volatility. The 5 / 100 price stability score says that is technically true and emotionally useless.
xvary composite
41
Below average overall. Translation: the upside case exists, but the burden of proof is still entirely on the pipeline.
source: institutional data
Institutional activity
institutional ownership data for BMEA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive